Caring Brands, Inc. (NASDAQ:CABR) Short Interest Down 71.0% in May

Caring Brands, Inc. (NASDAQ:CABR) saw a significant decrease in short interest in the month of May. As of May 15th, there was short interest totaling 5,492 shares, a decrease of 71.0% from the April 30th total of 18,964 shares. Based on an average trading volume of 100,261 shares, the short-interest ratio is presently 0.1 days. Approximately 0.1% of the shares of the company are short sold.

Institutional Trading of Caring Brands

An institutional investor recently bought a new position in Caring Brands stock. Jane Street Group LLC acquired a new position in shares of Caring Brands, Inc. (NASDAQ:CABR) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned approximately 0.25% of Caring Brands at the end of the most recent quarter.

Caring Brands Stock Down 4.3%

CABR stock traded down $0.05 during mid-day trading on Friday, reaching $1.11. 66,922 shares of the stock traded hands, compared to its average volume of 97,999. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.66 and a quick ratio of 5.62. Caring Brands has a 52 week low of $0.71 and a 52 week high of $5.35. The stock has a 50-day simple moving average of $1.08.

Caring Brands (NASDAQ:CABR) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.27) earnings per share (EPS) for the quarter.

Caring Brands Company Profile

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.